Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$6.71 -1.3%	$6.61	$4.66 ▼ $7.86	$110.21M	0.58	10,632 shs	3,777 shs
ETON Eton Pharmaceuticals	$14.01 +0.4%	$16.64	$3.22 ▼ $21.48	$375.72M	1.28	252,086 shs	4.39 million shs
PRTC PureTech Health	$17.15 -4.4%	$17.77	$13.30 ▼ $25.00	$411.93M	1.15	5,030 shs	40,178 shs
SANA Sana Biotechnology	$2.81 -2.1%	$2.19	$1.26 ▼ $7.40	$633.59M	1.78	3.68 million shs	5.96 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	-1.32%	-4.96%	+5.67%	+2.44%	+670,999,900.00%
ETON Eton Pharmaceuticals	+0.36%	+3.24%	-30.23%	+7.60%	+316.96%
PRTC PureTech Health	+0.41%	-5.87%	-3.65%	-11.32%	-27.88%
SANA Sana Biotechnology	-2.09%	+7.66%	+24.89%	+64.33%	-46.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	2.5913 of 5 stars	3.5	3.0	0.0	0.0	2.0	1.7	0.6
PRTC PureTech Health	2.5889 of 5 stars	3.8	5.0	0.0	0.0	2.2	0.0	0.0
SANA Sana Biotechnology	2.6809 of 5 stars	3.5	1.0	0.0	0.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	103.68% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	111.75% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	162.39% Upside
SANA Sana Biotechnology	3.00	Buy	$8.60	206.05% Upside

Current Analyst Ratings Breakdown

Latest BHST, ETON, PRTC, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$25.19M	4.37	N/A	N/A	$0.08 per share	83.88
ETON Eton Pharmaceuticals	$39.01M	9.63	N/A	N/A	$0.94 per share	14.90
PRTC PureTech Health	$4.83M	85.29	$2.39 per share	7.19	$17.04 per share	1.01
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.91M	-$0.50	N/A	N/A	N/A	-31.30%	-307.04%	-33.21%	8/14/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	28.02	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/30/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)

Latest BHST, ETON, PRTC, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.51	0.30
ETON Eton Pharmaceuticals	1.23	1.97	1.43
PRTC PureTech Health	N/A	9.33	9.33
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
ETON Eton Pharmaceuticals	27.86%
PRTC PureTech Health	0.04%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
ETON Eton Pharmaceuticals	16.03%
PRTC PureTech Health	5.30%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.42 million	N/A	N/A
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
PRTC PureTech Health	100	24.02 million	22.75 million	Not Optionable
SANA Sana Biotechnology	380	225.48 million	157.61 million	Optionable

BHST, ETON, PRTC, and SANA Headlines

Recent News About These Companies

Sana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.com

June 26 at 6:24 PM | investing.com

Sana Biotechnology (SANA) Receives a Buy from Citizens JMP

June 26 at 6:24 PM | theglobeandmail.com

Sana Biotechnology (NASDAQ:SANA) Earns Market Outperform Rating from JMP Securities

June 26 at 2:13 AM | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 4.5% - Time to Sell?

June 25 at 12:13 PM | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Consensus Price Target from Brokerages

June 25 at 2:13 AM | americanbankingnews.com

BofA Remains Bullish on Sana Biotechnology (SANA)

June 24, 2025 | insidermonkey.com

Sana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP Securities

June 24, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 17.2% - Should You Buy?

June 23, 2025 | marketbeat.com

Sana Biotechnology stock soars after positive diabetes treatment results

June 23, 2025 | investing.com

Two Biotech Stocks Poised For Big Moves On Monday

June 23, 2025 | benzinga.com

Sana Biotechnology Shares Climb on Positive Diabetes Study Results

June 23, 2025 | marketwatch.com

Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes

June 23, 2025 | quiverquant.comQ

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

June 23, 2025 | globenewswire.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from Analysts

June 22, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Clarius Group LLC

June 20, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.3% - Still a Buy?

June 17, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's Why

June 11, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?

June 10, 2025 | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 8, 2025 | marketbeat.com

Biggest Stocks in NASDAQ Featuring Sana Biotechnology and Kalkine

June 7, 2025 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST, ETON, PRTC, and SANA Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$6.71 -0.09 (-1.32%)

As of 06/27/2025 02:45 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Eton Pharmaceuticals NASDAQ:ETON

$14.01 +0.05 (+0.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$14.03 +0.02 (+0.14%)

As of 06/27/2025 05:50 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

PureTech Health NASDAQ:PRTC

$17.26 -0.68 (-3.79%)

As of 06/27/2025 04:00 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$2.81 -0.06 (-2.09%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.81 0.00 (0.00%)

As of 06/27/2025 07:43 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time